Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction

Chenyu Li, Donglu Qin, Jiarui Hu, Yang Yang, Die Hu, Bilian YuFrontiers in Immunology 2022 · DOI

This review article, published in Frontiers in Immunology, synthesizes current research to argue that "obese HFpEF" (Heart Failure with preserved Ejection Fraction) is a distinct clinical phenotype driven by a specific culprit: inflamed adipose tissue. The authors detail how overnutrition triggers a systemic inflammatory cascade—centered on the NLRP3 inflammasome—that ultimately leads to maladaptive cardiac remodeling and failure.

TL;DR

Obese HFpEF is not just a consequence of "extra weight," but a specific inflammatory disease driven by nutrient-overloaded adipose tissue. This review identifies the NLRP3 inflammasome as the key molecular bridge between metabolic stress and cardiac dysfunction, suggesting that targeted anti-inflammatory therapies are the next frontier for treatment.

What Problem Does This Paper Address?

Heart failure is traditionally categorized by ejection fraction (EF). While we have many treatments for heart failure with reduced ejection fraction (HFrEF), patients with HFpEF (EF > 50%)—who represent more than half of all heart failure cases—lack adequate clinical therapies.

Obesity is a massive risk factor for HFpEF, yet the exact mechanistic link has been fuzzy. This paper addresses the "why" and "how" by moving beyond simple hemodynamics. It explores the hypothesis that overnutrition causes adipose tissue to become a source of systemic "low-grade" inflammation, which then "poisons" the heart through metabolic reprogramming and structural damage.

Methods

As a review paper, the authors did not conduct new lab experiments but instead performed a comprehensive meta-analysis of:

  • Clinical Phenotyping: Comparing the unique hemodynamic and structural signatures of obese vs. non-obese HFpEF patients.
  • Molecular Pathways: Mapping the signaling cascades from nutrient overload to the activation of the NLRP3 inflammasome and subsequent cytokine release (IL-1β, IL-6, TNF-α).
  • Translational Benchmarking: Evaluating the "translational value" of various animal models (e.g., HFD-fed mice, ZSF1 rats, and "multi-hit" models) against human diagnostic scores like H2FPEF and HFA-PEFF.

Datasets

The paper synthesizes data from several landmark clinical trials and experimental frameworks:

  • Clinical Trials: Including CANTOS (canakinumab), D-HART (anakinra), and the recent SGLT2 inhibitor trials (DELIVER and EMPEROR-Preserved).
  • Animal Models: A detailed comparison of "one-hit" (e.g., leptin-deficient ob/ob mice), "two-hit" (e.g., HFD + L-NAME), and "multi-hit" models (HFD + aging + Ang II) to see which best mimics human pathology.

Key Insights and Ideas

  • Adipose as an Endocrine Organ: Adipose tissue isn't just a storage bin; when overloaded, it becomes dysfunctional. Specifically, Epicardial Adipose Tissue (EAT)—the fat physically touching the heart—secretes pro-inflammatory adipokines directly into the myocardium via paracrine signaling.
  • The NLRP3 Culprit: The NLRP3 inflammasome acts as a metabolic sensor. It detects "danger signals" like excess free fatty acids (FFAs) and ceramides, triggering the maturation of IL-1β and IL-18, which drive cardiac fibrosis and stiffening.
  • Metabolic Reprogramming: The paper highlights a "vicious cycle" where cardiomyocytes shift toward excessive fatty acid oxidation (leading to oxidative stress), while cardiac macrophages shift toward aerobic glycolysis (M1 polarization), fueling further inflammation.
  • The "BNP Paradox": Interestingly, obese HFpEF patients often have lower levels of Brain Natriuretic Peptide (BNP)—a standard biomarker for heart failure—because adipose tissue actively degrades it. This can lead to underdiagnosis in obese populations.

Key Results

  • Structural Signatures: Obese HFpEF is characterized by concentric left ventricular hypertrophy, increased epicardial fat thickness, and microvascular rarefaction (a decrease in the density of small blood vessels in the heart).
  • Therapeutic Efficacy:
    • SGLT2 Inhibitors: These are currently the most successful "indirect" anti-inflammatories, showing significant reductions in HF hospitalizations.
  • IL-1 Blockade: Trials like D-HART showed that blocking IL-1 (via anakinra) significantly improved peak oxygen consumption ($VO_2$) and exercise capacity in HFpEF patients.
  • Ketone Bodies: β-hydroxybutyrate (BHB) was identified as a potent endogenous inhibitor of the NLRP3 inflammasome, suggesting that nutritional interventions (like ketogenic diets or BHB supplements) might mitigate HFpEF.

Limitations and Future Work

  • Model Mismatch: Most current animal models rely on leptin deficiency (ob/ob or db/db), which doesn't accurately reflect human obesity (where leptin levels are usually high but the body is resistant).
  • Sex Differences: HFpEF is more prevalent in women, but many preclinical studies still skew toward male animals. The authors call for more "multi-hit" models that incorporate sex and aging.
  • Targeting IL-6: While IL-1 inhibitors show promise, the role of IL-6—a major downstream cytokine—remains a key area for future clinical investigation in HFpEF.

Summary updated

Abstract

The incidence of heart failure with preserved ejection fraction is increasing in patients with obesity, diabetes, hypertension, and in the aging population. However, there is a lack of adequate clinical treatment. Patients with obesity-related heart failure with preserved ejection fraction display unique pathophysiological and phenotypic characteristics, suggesting that obesity could be one of its specific phenotypes. There has been an increasing recognition that overnutrition in obesity causes adipose tissue expansion and local and systemic inflammation, which consequently exacerbates cardiac remodeling and leads to the development of obese heart failure with preserved ejection fraction. Furthermore, overnutrition leads to cellular metabolic reprogramming and activates inflammatory signaling cascades in various cardiac cells, thereby promoting maladaptive cardiac remodeling. Growing evidence indicates that the innate immune response pathway from the NLRP3 inflammasome, to interleukin-1 to interleukin-6, is involved in the generation of obesity-related systemic inflammation and heart failure with preserved ejection fraction. This review established the existence of obese heart failure with preserved ejection fraction based on structural and functional changes, elaborated the inflammation mechanisms of obese heart failure with preserved ejection fraction, proposed that NLRP3 inflammasome activation may play an important role in adiposity-induced inflammation, and summarized the potential therapeutic approaches.
BibTeX
@inproceedings{li2022inflamed,
  author = {Chenyu Li and Donglu Qin and Jiarui Hu and Yang Yang and Die Hu and Bilian Yu},
  title = {{Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.947147},
}
Figure